The Latest Cardiac and Vascular News
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Insight, Inc., a U.S. developer of wearable medical devices and diagnostic software, announced today that the company continues to experience a steady beat of market traction and industry endorsement with a recent infusion of $4.5 million into their new C-1 round of funding, currently capped at $10 […]
LAKE FOREST, Calif., Aug. 30, 2017 – NaviGate Cardiac Structures Inc. (“NCSI”) announced today that its GATE™ catheter-guided tricuspid atrioventricular valved stent (A VS) was implanted through the jugular vein six weeks ago into a patient’s transplanted heart that was failing due to severe tricuspid valve insufficiency. The successful implantation […]
MOUNTAIN VIEW, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) — Vascular Dynamics, Inc. (VDI), a privately held medical device company developing novel solutions for the treatment of hypertension, today announced European results of the company’s first-in-human trial of its MobiusHD®implant published in The Lancet. The publication reported an average reduction of 24-hour […]
VANCOUVER, Sept. 5, 2017 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ, TSX: NVCN) today announced the European Heart Journal published a clinical review of its Neovasc Reducer™ (“Reducer”) device for the treatment of refractory/persistent angina pectoris, a common and disabling medical condition, and a major public health problem that affects […]
AACHEN, Germany–(BUSINESS WIRE)–Protembis GmbH, a privately held medical device company, announced today the first clinical applications of its ProtEmbo® Cerebral Protection System to complement a transcatheter aortic valve replacement (TAVR) procedure. The ProtEmbo® System is an intra-aortic filter device that deflects embolic material arising during TAVR away from the brain. Darren Mylotte, […]
REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that Anthem Blue Cross Blue Shield, Blue Shield of California, and Blue Cross and Blue Shield of Alabama have each issued a positive medical policy for the HeartFlow® FFRct Analysis, a first-of-its-kind noninvasive technology that helps clinicians diagnose and treat patients with suspected coronary artery […]
ABBOTT PARK, Ill., Aug. 30, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified version of its AMPLATZER™ device designed to correct a common congenital heart defect that occurs in approximately 80,000 i,ii pre-term infants in the U.S. each year. […]
Landmark Data Published by The Lancet Demonstrates Statistically Significant Lower Event Rates with Orsiro BARCELONA, Spain, August 28, 2017 – BIOTRONIK today announced data from the BIOFLOW-V randomized trial comparing Orsiro1 and Xience2 drug-eluting stents (DES) with 12-month target lesion failure (TLF) as the primary endpoint proving non-inferiority. Results presented at the […]
Global collaboration aims to accelerate access to tools to determine extent of coronary artery disease and improve patient care Amsterdam, the Netherlands and Redwood City, Calif. – Royal Philips (NYSE: PHG, AEX: PHIA) and HeartFlow, Inc. announced today that they have entered into a collaboration agreement with the goal of […]
RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® dual therapy was used instead of warfarin triple therapy. Both Pradaxa® doses tested in RE-DUAL PCI™ have been approved for stroke prevention in atrial fibrillation. Data were presented as a late-breaker at the ESC Congress 20171 and published in the […]
